trending Market Intelligence /marketintelligence/en/news-insights/trending/sWoE-I88d4VsSCXEbi-lYw2 content esgSubNav
In This List

PharmaMar lung cancer drug reduces tumor size in phase 1/2 study

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


PharmaMar lung cancer drug reduces tumor size in phase 1/2 study

Pharma Mar SA said a combination of Zepsyre and chemotherapy reduced the tumor size of patients with relapsed small cell lung cancer in a phase 1/2 trial.

The Zepsyre phase 1/2 trials, conducted in 27 patients, showed that a combination of the drug and doxorubicin is better than topotecan alone. The combination had a progression-free survival of 5.3 months compared to topotecan's historical data of 3.1 to 3.5 months progression-free survival.

Further, the combination also demonstrated a 37% objective response rate versus the topotecan rates of between 17% and 24%.

The results of the trial were presented by PharmaMar at the International Association for the Study of Lung Cancer's World Conference on Lung Cancer held in Japan.